

AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the following Listing of Claims.*

Listing of Claims:

1. (Currently amended) An isolated polynucleotide selected from the group consisting of:
 - (a) a polynucleotide comprising 15 nucleotides of SEQ ID NO: 154, wherein the 15 nucleotides comprises the nucleotide sequence of SEQ ID NO: 90; and
 - (b) a polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 155[[:]]
 - ~~(c) a polynucleotide comprising 15 nucleotides of SEQ ID NO: 154, wherein the 15 nucleotides comprise a sequence that comprises a T at the position that corresponds to position 6 of SEQ ID NO: 90; and~~
 - ~~(d) a polynucleotide encoding a polypeptide, wherein said polypeptide comprises a sequence corresponding to SEQ ID NO: 155, and comprises an amino acid substitution of T to M at the position that corresponds to position 21 of SEQ ID NO: 155.~~
2. - 3. (Canceled).
4. (Previously presented) A vector comprising the polynucleotide of claim 1.
5. (Previously presented) The vector of claim 4, wherein the polynucleotide is operatively linked to expression control sequences allowing expression in prokaryotic or eukaryotic cells.

* The Advisory Action stated that the amendments filed March 25, 2009 were not entered. The Listing of Claims, thus, is based on claims pending as of the November 25, 2008 Office Action.

6. (Previously presented) An isolated host cell genetically engineered with the polynucleotide of claim 1 or the vector of claim 4 or 5.
- 7.-11. (Canceled).
12. (Previously presented) An isolated polynucleotide fully complementary to a polynucleotide of claim 1.
13. (Previously presented) A vector comprising the nucleic acid molecule of claim 12.
- 14-36. (Canceled).
37. (Previously presented) A primer or probe selected from the group consisting of:
 - (a) an oligonucleotide of about 15 to 50 nucleotides in length of SEQ ID NO: 154 comprising SEQ ID NO:90; and
 - (b) an oligonucleotide that is fully complementary to the oligonucleotide of (a).
38. (Canceled).
39. (Previously presented) A composition comprising the polynucleotide of claim 1.
40. (Previously presented) The composition of claim 39 which is a diagnostic composition.
41. (Currently amended) An isolated polynucleotide selected from the group consisting of:
 - (a) ~~a polynucleotide comprising a nucleotide sequence from positions 157 to 171 of SEQ ID NO:154,~~
 - (b) ~~a polynucleotide comprising the nucleotide sequence of positions 158 to 172 of SEQ ID NO:154;~~
 - (c) ~~a polynucleotide comprising the nucleotide sequence of positions 159 to 173 of SEQ ID NO:154;~~

~~(d)~~ — a polynucleotide comprising the nucleotide sequence of positions 160 to 174 of
SEQ ID NO:154;

~~(e)~~ — a polynucleotide comprising the nucleotide sequence of positions 161 to 175 of
SEQ ID NO:154;

~~(f)~~(a) a polynucleotide comprising the nucleotide sequence of positions 162 to 176 of
SEQ ID NO:154;

~~(g)~~(b) a polynucleotide comprising the nucleotide sequence of positions 163 to 177 of
SEQ ID NO:154;

~~(h)~~(c) a polynucleotide comprising the nucleotide sequence of positions 164 to 178 of
SEQ ID NO:154;

~~(i)~~(d) a polynucleotide comprising the nucleotide sequence of positions 165 to 179 of
SEQ ID NO:154;

~~(j)~~(e) a polynucleotide comprising the nucleotide sequence of positions 166 to 180 of
SEQ ID NO:154;

~~(k)~~ — a polynucleotide comprising the nucleotide sequence of positions 167 to 181 of
SEQ ID NO:154;

~~(l)~~ — a polynucleotide comprising the nucleotide sequence of positions 168 to 182 of
SEQ ID NO:154;

~~(m)~~ — a polynucleotide comprising the nucleotide sequence of positions 169 to 183 of
SEQ ID NO:154;

~~(n)~~ — a polynucleotide comprising the nucleotide sequence of positions 170 to 184 of
SEQ ID NO:154;

~~(o)~~ — a polynucleotide comprising the nucleotide sequence of positions 171 to 185 of
SEQ ID NO:154; and

~~(p)~~(f) a polynucleotide comprising the nucleotide sequence of the full complement of
any of (a) to ~~(o)~~(e).